ALLO · ISSUER CIK 1737287
Allogene Therapeutics, Inc.
Between Aug 1, 2026 and Oct 29, 2026, 2 Allogene Therapeutics, Inc. insiders reported $0.00 of open-market purchases and $112K of sales on SEC Form 4.
↗2 insiders filed
Original Form 4 filings from Aug 1, 2026 to Oct 29, 2026. 0 of 2 sales were reported under a 10b5-1 plan.
$0.00Insider buying
$112KInsider selling
−$112KNet open-market
Oct 23, 2026Latest filing
| Ticker | Insider | Type | Owned | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Oct 23, 202616:48 | Oct 21, 2026 | ALLO | CHIEF FINANCIAL OFFICER | S · Sell | $1.34 | −36,342 | 1,045,877 | -3% | −$49K | ||
| Aug 25, 202616:43 | Aug 21, 2026 | ALLO | SVP, General Counsel | S · Sell | $2.12 | −29,697 | 488,267 | -6% | −$63K |